Advertisement

Application of Anti-Ligand Antibodies to Inhibit Notch Signaling

  • Jun-ichiro Koga
  • Masanori AikawaEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1187)

Abstract

Emerging evidence suggests that Notch signaling not only regulates biological processes during development but also participates in the pathogenesis of various diseases in adults, including tumor angiogenesis, hematopoietic malignancies, and cardiometabolic syndromes. Notch signaling involves several ligands and receptors that have unique and overlapping functions. Therefore, blocking function of a ligand or receptor with a neutralizing antibody is a useful approach to examine the specific role of each Notch component. In addition, administration of Notch signaling blocking antibodies in experimental animals offers important insights into clinical translation of Notch biology. In this chapter, we describe examples of in vitro and in vivo loss-of-function experiments with blockade of Notch ligands, particularly Delta-like ligand 4 (Dll4).

Key words

Notch ligand Blocking antibody Delta-like ligand 4 Luciferase assay Nucleofection 

Notes

Acknowledgements

This work was supported in part by a National Institutes of Health grant R01HL107550 to M.A.

References

  1. 1.
    D’Souza B, Meloty-Kapella L, Weinmaster G (2010) Canonical and non-canonical Notch ligands. Curr Top Dev Biol 92:73–129PubMedCrossRefGoogle Scholar
  2. 2.
    Kopan R, Ilagan MX (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137:216–233PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Kovall RA, Blacklow SC (2010) Mechanistic insights into Notch receptor signaling from structural and biochemical studies. Curr Top Dev Biol 92:31–71PubMedCrossRefGoogle Scholar
  4. 4.
    Cordle J, Johnson S, Tay JZ et al (2008) A conserved face of the Jagged/Serrate DSL domain is involved in Notch trans-activation and cis-inhibition. Nat Struct Mol Biol 15:849–857PubMedCentralPubMedGoogle Scholar
  5. 5.
    Six E, Ndiaye D, Laabi Y et al (2003) The Notch ligand Delta1 is sequentially cleaved by an ADAM protease and gamma-secretase. Proc Natl Acad Sci U S A 100:7638–7643PubMedCentralPubMedGoogle Scholar
  6. 6.
    Parr-Sturgess CA, Rushton DJ, Parkin ET (2010) Ectodomain shedding of the Notch ligand Jagged1 is mediated by ADAM17, but is not a lipid-raft-associated event. Biochem J 432:283–294PubMedGoogle Scholar
  7. 7.
    Jarriault S, Brou C, Logeat F et al (1995) Signalling downstream of activated mammalian Notch. Nature 377:355–358PubMedGoogle Scholar
  8. 8.
    Noguera-Troise I, Daly C, Papadopoulos NJ et al (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444:1032–1037PubMedGoogle Scholar
  9. 9.
    Ridgway J, Zhang G, Wu Y et al (2006) Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444:1083–1087PubMedGoogle Scholar
  10. 10.
    Real C, Remédio L, Caiado F et al (2011) Bone marrow-derived endothelial progenitors expressing Delta-like 4 (Dll4) regulate tumor angiogenesis. PLoS One 6:e18323PubMedCentralPubMedGoogle Scholar
  11. 11.
    Jenkins DW, Ross S, Veldman-Jones M et al (2012) MEDI0639: A novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo. Mol Cancer Ther 11:1650–1660PubMedGoogle Scholar
  12. 12.
    Fung E, Tung SM, Canner JP et al (2007) Delta-like 4 induces Notch signaling in macrophages: Implications for inflammation circulation 115:2948–2956Google Scholar
  13. 13.
    Fukuda D, Aikawa E, Swirski FK et al (2012) Notch ligand Delta-like 4 blockade attenuates atherosclerosis and metabolic disorders. Proc Natl Acad Sci U S A 109:E1868–E1877PubMedCentralPubMedGoogle Scholar
  14. 14.
    Moriyama Y, Sekine C, Koyanagi A et al (2008) Delta-like 1 is essential for the maintenance of marginal zone B cells in normal mice but not in autoimmune mice. Int Immunol 20:763–773PubMedGoogle Scholar
  15. 15.
    Lai PY, Tsai CB, Tseng MJ (2013) Active form Notch4 promotes the proliferation and differentiation of 3 T3-L1 preadipocytes. Biochem Biophys Res Commun 430:1132–1139PubMedGoogle Scholar
  16. 16.
    Yamanda S, Ebihara S, Asada M et al (2009) Role of ephrinB2 in nonproductive angiogenesis induced by Delta-like 4 blockade. Blood 113:3631–3639PubMedGoogle Scholar
  17. 17.
    Oishi H, Sunamura M, Egawa S et al (2010) Blockade of delta-like ligand 4 signaling inhibits both growth and angiogenesis of pancreatic cancer. Pancreas 39:897–903PubMedGoogle Scholar
  18. 18.
    Hemati N, Ross SE, Erickson RL et al (1997) Signaling pathways through which insulin regulates CCAAT/enhancer binding protein alpha (C/EBPalpha) phosphorylation and gene expression in 3 T3-L1 adipocytes. Correlation with GLUT4 gene expression. J Biol Chem 272:25913–25919PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.The Center for Excellence in Vascular BiologyBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA
  2. 2.The Center for Excellence in Vascular Biology and Center for Interdisciplinary Cardiovascular SciencesBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations